Lipum: Interview with analyst Kevin Sule (video)

Redeye recently initiated coverage of Lipum, a Swedish biotech company developing novel therapeutics for chronic inflammatory diseases. Analyst Kevin Sule talks us through the investment case.

RR

Redaktionen Redeye

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.